Fisher Asset Management LLC Has $256,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Fisher Asset Management LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 11.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 962 shares of the medical instruments supplier’s stock after selling 125 shares during the quarter. Fisher Asset Management LLC’s holdings in Becton, Dickinson and were worth $256,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. CWM LLC bought a new stake in Becton, Dickinson and during the 4th quarter worth approximately $566,000. Qube Research & Technologies Ltd increased its holdings in Becton, Dickinson and by 457.1% during the 4th quarter. Qube Research & Technologies Ltd now owns 201,970 shares of the medical instruments supplier’s stock worth $50,791,000 after purchasing an additional 165,714 shares in the last quarter. Centaurus Financial Inc. increased its holdings in Becton, Dickinson and by 8.5% during the 4th quarter. Centaurus Financial Inc. now owns 525 shares of the medical instruments supplier’s stock worth $132,000 after purchasing an additional 41 shares in the last quarter. FDx Advisors Inc. increased its holdings in Becton, Dickinson and by 25.7% during the 4th quarter. FDx Advisors Inc. now owns 4,799 shares of the medical instruments supplier’s stock worth $1,207,000 after purchasing an additional 982 shares in the last quarter. Finally, AGF Investments Inc. grew its holdings in shares of Becton, Dickinson and by 87.0% in the fourth quarter. AGF Investments Inc. now owns 1,496 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 696 shares in the last quarter. 86.58% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Price Performance

Becton, Dickinson and stock opened at $254.23 on Friday. The company has a market cap of $72.47 billion, a price-to-earnings ratio of 43.83, a PEG ratio of 3.41 and a beta of 0.59. The business’s 50 day simple moving average is $244.97 and its 200 day simple moving average is $256.22. Becton, Dickinson and Company has a 12 month low of $231.46 and a 12 month high of $280.62. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $4.64 billion for the quarter, compared to the consensus estimate of $4.47 billion. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The business’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.74 earnings per share. Sell-side analysts forecast that Becton, Dickinson and Company will post 11.18 EPS for the current year.

Becton, Dickinson and Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 9th will be given a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 annualized dividend and a dividend yield of 1.37%. Becton, Dickinson and’s dividend payout ratio is currently 60.00%.

Insiders Place Their Bets

In related news, VP Thomas J. Spoerel sold 443 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $260.00, for a total value of $115,180.00. Following the sale, the vice president now owns 1,058 shares in the company, valued at $275,080. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on BDX. Citigroup lowered Becton, Dickinson and from a “neutral” rating to a “sell” rating and reduced their target price for the company from $265.00 to $235.00 in a report on Monday, July 11th. Stifel Nicolaus reduced their target price on Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. StockNews.com raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Wednesday. Wells Fargo & Company raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a report on Friday, June 24th. Finally, Piper Sandler dropped their price objective on Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $270.88.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Further Reading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.